Inside FDA’s Debates On ‘Breakthrough’
Executive Summary
Office of New Drugs Director Jenkins provides a peek into the Medical Policy Council’s efforts to consistently interpret and implement the ‘breakthrough therapy’ program.
You may also be interested in...
US FDA Hoping To Solve Drug-Software Issues With Digital Health Working Group
As more applications include software components, group wants assessors to apply best practices from CDRH to CDER whenever possible.
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials
Cidara developed the antifungal for candidemia/invasive candidiasis pursuant to the FDA’s 2017 ‘Unmet Need guidance,’ which provides an avenue for approval with a 'limited use' indication based on a streamlined development program. Some of the guidance recommendations also have been leveraged under the LPAD pathway.